Opportunities

Funding the Future of Bio-Medicines

“The breadth and depth of biology at Stanford is second to none. If this expertise can be more effectively coupled with state-of-the-art molecular design and analysis, the university could accelerate the engineering of innovative drug prototypes that will, in turn, spawn the next generation of medicines that cure disease or reduce the cost of hospitalization or professional services.”

Chaitan Khosla

Director

Open Requests for Proposals

Spring 2024

Small Molecule Therapeutics

The Stanford Innovative Medicines Accelerator (IMA) is accepting proposals for projects that address two major challenges in small molecule drug discovery: adaptation of laboratory-grade assays to high-throughput screening (HTS) formats to identify starting points for medicinal chemistry and optimization of lead compounds into drug prototypes.

Spring 2024

Experimental Human Biology

The Stanford Innovative Medicines Accelerator (IMA) is accepting proposals to address unmet therapeutic needs through human subjects research. Through this solicitation, the IMA seeks to support human subjects research that is ripe for translation by fostering the clinical development of new or extending the use of existing drugs, vaccines, and companion biomarkers that directly enable drug development. This could be a proof of concept trial for a new medication, a new indication for an existing proprietary or generic drug, or a companion biomarker.  

Closed Requests for Proposals

Winter 2022

Experimental Human Biology

Stanford University’s Innovative Medicines Accelerator (IMA) aims to accelerate the prototyping of innovative medicines and vaccines, and to enable hypothesis-driven studies in human subjects. The purpose of this request for letters of intent (LOI) is to leverage capacity and infrastructure at Stanford to address unmet medical needs through human subject research. 

Fall 2021

Molecular Therapeutics

The Innovative Medicines Accelerator (IMA) aims to accelerate the translation of scientific discoveries at Stanford University into new therapeutics that impact human health. Identification of medicinally appropriate lead molecules and their subsequent engineering into Drug Prototypes are two major challenges in drug discovery. 

Fall 2021

Tonsils-in-a-Dish Vaccine Prototyping

Stanford University’s Innovative Medicines Accelerator (IMA) aims to accelerate the prototyping of innovative medicines and vaccines, and to enable hypothesis-driven studies on human subjects. The purpose of this request for proposals (RFP) is to leverage a recent technological advance to prototype new vaccines for infectious and non-infectious diseases.

Licensing & Partnering

For information on licensing technologies or becoming a partner, contact Alliance Director Paul Humphries.